Regulation of microRNAs by Natural Agents: An Emerging Field in Chemoprevention and Chemotherapy Research
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
ABSTRACTIn recent years, microRNAs have received greater attention in cancer research. These small, non-coding RNAs could inhibit target gene expression by binding to the 3′ untranslated region of target mRNA, resulting in either mRNA degradation or inhibition of translation. miRNAs play important roles in many normal biological processes; however, studies have also shown that aberrant miRNA expression is correlated with the development and progression of cancers. The miRNAs could have oncogenic or tumor suppressor activities. Moreover, some miRNAs could regulate formation of cancer stem cells and epithelial-mesenchymal transition phenotype of cancer cells which are typically drug resistant. Furthermore, miRNAs could be used as biomarkers for diagnosis and prognosis, and thus miRNAs are becoming emerging targets for cancer therapy. Recent studies have shown that natural agents including curcumin, isoflavone, indole-3-carbinol, 3,3′-diindolylmethane, (-)-epigallocatechin-3-gallate, resveratrol, etc. could alter miRNA expression profiles, leading to the inhibition of cancer cell growth, induction of apoptosis, reversal of epithelial-mesenchymal transition, or enhancement of efficacy of conventional cancer therapeutics. These emerging results clearly suggest that specific targeting of miRNAs by natural agents could open newer avenues for complete eradication of tumors by killing the drug-resistant cells to improve survival outcome in patients diagnosed with malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Wightman, B., Ha, I., & Ruvkun, G. (1993) · Cell · doi:10.1016/0092-8674(93)90530-4 · Cited by 4,292 · cited 2×
“The lin-4 was found to contain sequences complementary to a repeated sequence element in the 3′ untranslated region (UTR) of lin-14 mRNA, suggesting that miRNA lin-4 could regulate lin-14 mRNA translation via an antisense RNA-RNA interaction (1,2).”
BackgroundMicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 1×
“Furthermore, the activity of miR-122 and its downstream genes was altered upon anti-sense oligonucleotide administration (97).”
BackgroundUnique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023 · cited 1×
“It was found that high miR-155 and low let-7a expression correlated with poor survival (83).”
BackgroundProcessing of primary microRNAs by the Microprocessor complex
Denli, A. M., Tops, B. B. J., Plasterk, R. H. A., Ketting, R. F., & Hannon, G. J. (2004) · Nature · doi:10.1038/nature03049 · Cited by 2,784
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010 · cited 3×
“The increased expression of miR-34a could result in increased apoptosis and also cause changes in the expression of genes related to cell cycle progression, apoptosis, DNA repair, and angiogenesis (68).”
BackgroundAsangani, I. A., Rasheed, S. A. K., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., & Allgayer, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210856 · Cited by 1,882 · cited 1×
“expression (45), demonstrating that Pdcd4 is a target of”
BackgroundSi, M.-L., Zhu, S., Wu, H., Lu, Z., Wu, F., & Mo, Y.-Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210083 · Cited by 1,600
The let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells
Johnson, C. D., Esquela-Kerscher, A., Stefani, G., Byrom, M., Kelnar, K., Ovcharenko, D., Wilson, M., Wang, X., Shelton, J., Shingara, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1083 · Cited by 1,224 · cited 1×
“growth of lung, liver, and pancreatic cancer cells (8,60), suggesting the value of restoring tumor suppressor miRNAs in cancer treatment.”
BackgroundCirculating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149 · cited 1×
“Circulating miRNAs have also been used as potential biomarkers for drug-induced liver injury (93).”
BackgroundMicroRNA-21 Targets a Network of Key Tumor-Suppressive Pathways in Glioblastoma Cells
Papagiannakopoulos, T., Shapiro, A., & Kosik, K. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1305 · Cited by 705
Sequence-specific inhibition of small RNA function
Hutvágner, G., Simard, M. J., Mello, C. C., & Zamore, P. D. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020098 · Cited by 584
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., Mathe, E. A., Jen, J., Yang, P., Sugimura, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905234106 · Cited by 500
Lukiw, W. J., Zhao, Y., & Cui, J. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805371200 · Cited by 441
Ribas, J., Ni, X., Haffner, M., Wentzel, E. A., Salmasi, A. H., Chowdhury, W. H., Kudrolli, T. A., Yegnasubramanian, S., Luo, J., Rodriguez, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1448 · Cited by 416
Katiyar, S. K., Afaq, F., Perez, A., & Mukhtar, H. (2001) · Carcinogenesis · doi:10.1093/carcin/22.2.287 · Cited by 399
Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma
Pierson, J., Hostager, B., Fan, R., & Vibhakar, R. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9624-3 · Cited by 233
Cited by
Wang, H., Oo Khor, T., Shu, L., Su, Z.-Y., Fuentes, F., Lee, J.-H., & Tony Kong, A.-N. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012803833026 · Cited by 529
Pancreatic cancer: understanding and overcoming chemoresistance
Wang, Z., Li, Y., Ahmad, A., Banerjee, S., Azmi, A. S., Kong, D., & Sarkar, F. H. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.188 · Cited by 364
Self-citationEpigenetic changes induced by curcumin and other natural compounds
Reuter, S., Gupta, S. C., Park, B., Goel, A., & Aggarwal, B. B. (2011) · Genes & Nutrition · doi:10.1007/s12263-011-0222-1 · Cited by 362
Curcumin as an Alternative Epigenetic Modulator: Mechanism of Action and Potential Effects
Hassan, F.-U., Rehman, M. S.-U., Khan, M. S., Ali, M. A., Javed, A., Nawaz, A., & Yang, C. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00514 · Cited by 357
Wang, Z., Li, Y., Ahmad, A., Azmi, A. S., Kong, D., Banerjee, S., & Sarkar, F. H. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.07.001 · Cited by 343
Self-citation
Metadata
- Authors
- Li, Y., Kong, D., Wang, Z., & Sarkar, F. H.
- Venue
- Pharmaceutical Research
- Published
- 2010-03-20
- Volume
- 27
- Issue
- 6
- Pages
- 1027-1041
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1980920427
- Cited by
- 190
- References
- 18
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.